News & Events

of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such fi…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 17, 2026, Ana Hooker notified the Board of Directors (the “Board”) of Exagen Inc. (the “Company”) of her decision to resign as member of the Board, including all committees thereof, effective April 17, 2026 ("Effective Time"). Ms. Hooker was a member of the Audit Committee and chair of the Nominating and Corporate Governance Committee. Her…

of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such fi…

Results of Operations and Financial Condition. On January 11, 2026, Exagen Inc. (the “Company”) announced in a press release (the “Press Release”) certain select preliminary unaudited financial information and results of operations for the three months and year ended December 31, 2025, based on currently available information. A copy of the Press Release issued by the Company is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company’s financial closing procedures with respe…

of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such fi…

of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such fi…

Election of Director; Amendment of Non-Employee Director Compensation Program; Compensatory Arrangements of Certain Directors. On July 17, 2025, upon the recommendation of the Nominating and Corporate Governance Committee (“Nominating Committee”) of the Board of Directors (the “Board”) of Exagen Inc. (the “Company”), and pursuant to the bylaws of the Company, the Board appointed, effective as of July 17, 2025 (the “Effective Date”), Charles S. McKhann to serve as a Class III director, with an…

Entry into a Material Definitive Agreement. On May 8, 2025, Exagen Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) by and between Canaccord Genuity LLC (the “ Underwriter ”) relating to the issuance and sale of an aggregate of 3,350,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), to the Underwriter at a price to the public of $5.25 per share (the “ Offering ”). Pursuant to the ter…

of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such fi…

Regulation FD Disclosure. On April 28, 2025, the Company issued a press release announcing the entry into the Credit Agreement. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in the press release is being furnished, not filed, pursuant to

Entry into a Material Definitive Agreement. Entry into Perceptive Term Loan Facility On April 25, 2025 (the “Closing Date”), Exagen Inc. (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings IV, LP, as lender and administrative agent (“Perceptive”), which provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $75.0 million (the “Perceptive Term Loan Facility”). An initial tranche o…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information required by this

relating to the Warrant Certificate and the Warrant Shares is set forth under

of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such fi…